Foghorn Therapeutics Inc. (FHTX)

NASDAQ: FHTX · Real-Time Price · USD
7.38
-0.24 (-3.15%)
Dec 4, 2024, 4:00 PM EST - Market closed
-3.15%
Market Cap 410.28M
Revenue (ttm) 25.52M
Net Income (ttm) -91.22M
Shares Out 55.59M
EPS (ttm) -1.83
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 156,508
Open 7.67
Previous Close 7.62
Day's Range 7.17 - 7.80
52-Week Range 2.70 - 10.25
Beta 3.10
Analysts Strong Buy
Price Target 16.00 (+116.8%)
Earnings Date Nov 4, 2024

About FHTX

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myel... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Oct 23, 2020
Employees 116
Stock Exchange NASDAQ
Ticker Symbol FHTX
Full Company Profile

Financial Performance

In 2023, Foghorn Therapeutics's revenue was $34.16 million, an increase of 77.63% compared to the previous year's $19.23 million. Losses were -$98.43 million, -9.60% less than in 2022.

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for FHTX stock is "Strong Buy." The 12-month stock price forecast is $16.0, which is an increase of 116.80% from the latest price.

Price Target
$16.0
(116.80% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences

CAMBRIDGE, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by...

22 days ago - GlobeNewsWire

Foghorn Therapeutics Provides Third Quarter 2024 Financial and Corporate Update

First patient dosed with first-in-class SMARCA2(BRM) selective inhibitor FHD-909 (LY4050784) in Phase 1 trial with primary target population in SMARCA4(BRG1) mutated NSCLC

4 weeks ago - GlobeNewsWire

Foghorn Therapeutics Announces First Patient Dosed with First-in-Class Oral SMARCA2 Selective Inhibitor FHD-909 in a Phase 1 Trial for SMARCA4 Mutated Solid Tumors

Primary target patient population for the FHD-909 Phase 1 trial is  non-small cell lung cancer (NSCLC) Lilly leads the clinical development of the Phase 1 trial Foghorn's selective SMARCA2 oncology pr...

7 weeks ago - GlobeNewsWire

Foghorn Therapeutics to Participate in the BMO Oncology Summit

CAMBRIDGE, Mass., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by...

2 months ago - GlobeNewsWire

Foghorn Therapeutics Strengthens Leadership Team with Appointment of Anna Rivkin, Ph.D. as Chief Business Officer

CAMBRIDGE, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases b...

3 months ago - GlobeNewsWire

Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences in September

CAMBRIDGE, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by...

3 months ago - GlobeNewsWire

Foghorn Therapeutics Provides Second Quarter 2024 Financial and Corporate Update

Topline Phase 1 dose escalation data for FHD-286 in combination with decitabine, in relapsed and/or refractory AML patients, anticipated in the fourth quarter of 2024

4 months ago - GlobeNewsWire

Foghorn Therapeutics to Participate in Upcoming Investor Conferences in June

CAMBRIDGE, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by ...

6 months ago - GlobeNewsWire

Foghorn Therapeutics Raises Approximately $110 Million Through Registered Direct Offering to Advance Pipeline

Positions company to further leverage strength of platform and advance programs through multiple data readouts and clinical value inflection points

7 months ago - GlobeNewsWire

Foghorn Announces Pricing of Registered Direct Offering of Common Stock and Pre-Funded Warrants

CAMBRIDGE, Mass., May 20, 2024 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (“Foghorn”) (Nasdaq: FHTX) today announced the pricing of a registered direct offering of 12,743,039 shares of its common s...

7 months ago - GlobeNewsWire

Foghorn Therapeutics Provides First Quarter 2024 Financial and Corporate Update

Dose escalation in FHD-286 combination trial in AML continues to progress with clinical data expected in the second half of 2024; potential to be a first-in-class oral broad-based differentiation ther...

7 months ago - GlobeNewsWire

Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Kristian Humer as Chief Financial Officer

CAMBRIDGE, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases b...

8 months ago - GlobeNewsWire

Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs

First-in class BRM (SMARCA2) selective inhibitor FHD-909 demonstrated favorable tolerability and dose-dependent single agent activity in BRG1 mutated cancers preclinically; IND filing on track for Q2 ...

8 months ago - GlobeNewsWire

Foghorn Therapeutics to Participate in Needham's 23rd Annual Virtual Healthcare Conference

Company presentation and fireside chat on April 11th at 11:45 a.m. ET Company presentation and fireside chat on April 11th at 11:45 a.m. ET

8 months ago - GlobeNewsWire

Foghorn to Host Conference Call and Webcast on Pipeline of Potential First-in-Class Medicines in Conjunction with the 2024 AACR Annual Meeting

Company management will review key pipeline programs, including an update on FHD-286 for AML, new preclinical data for the BRM selective inhibitor FHD-909 and for its selective CBP and EP300 degrader ...

9 months ago - GlobeNewsWire

Foghorn Therapeutics Provides Financial Update for 2023 and 2024 Strategic Outlook

• Dose escalation in FHD-286 combination study in AML continues to progress; clinical data anticipated in the second half of 2024

9 months ago - GlobeNewsWire

Foghorn Therapeutics to Present New Preclinical Data at 2024 AACR Annual Meeting, Reflecting Advances with Multiple Potential First-in-Class Medicines, including the Selective Inhibitor of BRM, FHD-909

Poster presentation of FHD-909, a first-in-class oral BRM selective inhibitor, highlighting preclinical efficacy and safety in multiple mouse models of NSCLC; IND filing planned in Q2 2024

9 months ago - GlobeNewsWire

Foghorn Therapeutics to Participate in Cowen's 44th Annual Health Care Conference

CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by...

10 months ago - GlobeNewsWire

Foghorn Therapeutics Announces Clinical Data from Phase 1 Study of FHD-286, a Novel BRG1/BRM Inhibitor, in Patients with Advanced Hematologic Malignancies, to be Presented at American Society of Hematology Annual Meeting

CAMBRIDGE, Mass., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by...

1 year ago - GlobeNewsWire

Foghorn Therapeutics Provides Third Quarter 2023 Financial and Corporate Update

CAMBRIDGE, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by...

1 year ago - GlobeNewsWire

Foghorn Therapeutics Announces Clinical Data From Phase 1 Study of FHD-286 in Metastatic Uveal Melanoma to Be Presented at ESMO Congress

CAMBRIDGE, Mass., Oct. 13, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by...

1 year ago - GlobeNewsWire

Foghorn Therapeutics to Present Clinical and Pre-Clinical Data from Multiple Programs Across Its Diverse Pipeline at AACR-NCI-EORTC International Conference

CAMBRIDGE, Mass., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by...

1 year ago - GlobeNewsWire

Flagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development Officer

CAMBRIDGE, Mass. , Sept. 11, 2023 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, announced today the appointment of Amanda Kay as Senior Partner and Chief Business Developmen...

Other symbols: DNLIMCRBMRNAOMGASANA
1 year ago - PRNewsWire

Foghorn Therapeutics Announces First Patient Dosed in Phase 1 Combination Study of FHD-286 for Relapsed and/or Refractory AML

CAMBRIDGE, Mass., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious disease by ...

1 year ago - GlobeNewsWire

Foghorn Therapeutics: Ifs, Buts, And Clinical Holds

Foghorn Therapeutics Inc. stock has increased by 70% in the last 4 months after a clinical hold on their lead program was lifted. Foghorn's technology, called "gene traffic control," aims to regulate ...

1 year ago - Seeking Alpha